Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Work In Process (2022 - 2025)

BioXcel Therapeutics has reported Work In Process over the past 4 years, most recently at $368000.0 for Q4 2025.

  • Quarterly results put Work In Process at $368000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $368000.0 (changed N/A YoY), and the annual figure for FY2025 was $368000.0, changed.
  • Work In Process for Q4 2025 was $368000.0 at BioXcel Therapeutics, down from $387000.0 in the prior quarter.
  • Over the last five years, Work In Process for BTAI hit a ceiling of $708000.0 in Q4 2022 and a floor of $122000.0 in Q3 2022.
  • Median Work In Process over the past 4 years was $395000.0 (2022), compared with a mean of $437125.0.
  • Peak annual rise in Work In Process hit 395.9% in 2023, while the deepest fall reached 8.05% in 2023.
  • BioXcel Therapeutics' Work In Process stood at $708000.0 in 2022, then dropped by 8.05% to $651000.0 in 2023, then crashed by 40.55% to $387000.0 in 2024, then fell by 4.91% to $368000.0 in 2025.
  • The last three reported values for Work In Process were $368000.0 (Q4 2025), $387000.0 (Q2 2024), and $253000.0 (Q1 2024) per Business Quant data.